(Stroke. 2000;31:1046.)
© 2000 American Heart Association, Inc.
Original Contributions |
Economic Evaluation in Stroke Research
A Systematic Review
From the Department of Health Organization Policy and Economics, Maastricht University (S.M.A.A.E., A.J.H.A.A.), and the Department of Neurosurgery, University Hospital Maastricht (S.M.A.A.E., G.B.), Maastricht, the Netherlands.
Correspondence to Silvia Evers, Maastricht University, Dept. Health Organization Policy and Economics, PO Box 616, 6200 MD Maastricht, Netherlands. E-mail S.Evers{at}BEOZ.unimaas.nl
Background and Purpose—The purpose of this review is to provide insight into the quality of economic evaluation in the field of cerebrovascular diseases (CVD) on the basis of a systematic analysis.
Methods—A literature search was performed using several sources. Trial-based full economic evaluation studies, were included in this review. The quality of the studies was independently assessed by 2 reviewers using a checklist.
Results—Twenty-three articles were found to comply with our inclusion and exclusion criteria. Only a few studies mentioned the perspective of the study, and in these cases it was always the societal perspective. The majority of the studies were cost-minimization and cost-effectiveness analyses based on cohort studies. All studies included healthcare costs, and in some instances patient and family costs were considered. Costs were usually measured by tariffs. Clinical end points and mortality were used to measure effects. Cost and effect measurements were based on hospital records.
Conclusions—Only a few full economic evaluations have been undertaken in the domain of CVD. In most of the studies, the technical execution and methodology were limited.
Key Words: stroke • economics • review
This article has been cited by other articles:
 |
|
 |
|
  M. Stuart, C. Ryser, A. Levitt, S. Beer, J. Kesselring, S. Chard, and M. Weinrich Stroke Rehabilitation in Switzerland versus the United States: A Preliminary Comparison Neurorehabil Neural Repair, June 1, 2005; 19(2): 139 - 147. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Rundek, K. Nielsen, S. Phillips, K. C. Johnston, M. Hux, D. Watson, and for the GAIN Americas Investigators Health Care Resource Use After Acute Stroke in the Glycine Antagonist in Neuroprotection (GAIN) Americas Trial Stroke, June 1, 2004; 35(6): 1368 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M.A.A. Evers, J. N. Struijs, A. J.H.A. Ament, M. L.L. van Genugten, J. C. Jager, and G. A.M. van den Bos International Comparison of Stroke Cost Studies Stroke, May 1, 2004; 35(5): 1209 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Holloway and A. W. Dick Editorial Comment--Stroke Cost-Effectiveness Research: Are Acceptability Curves Acceptable? Stroke, January 1, 2004; 35(1): 203 - 204. [Full Text] [PDF]
|
|
|
|
|
|
A. Patel, M. Knapp, I. Perez, A. Evans, and L. Kalra Alternative Strategies for Stroke Care: Cost-Effectiveness and Cost-Utility Analyses From a Prospective Randomized Controlled Trial Stroke, January 1, 2004; 35(1): 196 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Teng, N. E. Mayo, E. Latimer, J. Hanley, S. Wood-Dauphinee, R. Cote, and S. Scott Costs and Caregiver Consequences of Early Supported Discharge for Stroke Patients Stroke, February 1, 2003; 34(2): 528 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jefferson, V. Demicheli, and L. Vale Quality of Systematic Reviews of Economic Evaluations in Health Care JAMA, June 5, 2002; 287(21): 2809 - 2812. [Abstract] [Full Text] [PDF]
|
|